Mehmet Sofuoglu1, Maria Mouratidis, Marc Mooney. 1. Yale University, School of Medicine, Department of Psychiatry, VA Connecticut Healthcare System, West Haven, CT, USA. Mehmet.Sofuoglu@yale.edu
Abstract
BACKGROUND:Progesterone, a steroid hormone, has been implicated in many CNS functions including reward, cognition, and neuroprotection. The goal of this study was to examine the dose-dependent effects of progesterone on cognitive performance, smoking urges, and smoking behavior in smokers. METHODS:Thirty female and thirty-four male smokers participated in a double-blind, placebo-controlled study. Female smokers were in the early follicular phase of their menstrual cycle during study participation. Smokers were randomly assigned to either 200 or 400mg/day of progesterone or placebo, given in two separate doses, during clinic visit. The first 3 days of the treatment period, smokers abstained from smoking, which was verified with breath CO levels. Smokers attended an experimental session on day 4 where the number of cigarettes smoked were recorded starting 2h after the medication treatment. RESULTS:Progesterone treatment, 200mg/day, significantly improved cognitive performance in the Stroop and the Digit Symbol Substitution Test. Progesterone at 400mg/day was associated with reduced urges for smoking but did not change ad lib smoking behavior. CONCLUSIONS: These findings suggest a potential therapeutic value of progesterone for smoking cessation.
RCT Entities:
BACKGROUND:Progesterone, a steroid hormone, has been implicated in many CNS functions including reward, cognition, and neuroprotection. The goal of this study was to examine the dose-dependent effects of progesterone on cognitive performance, smoking urges, and smoking behavior in smokers. METHODS: Thirty female and thirty-four male smokers participated in a double-blind, placebo-controlled study. Female smokers were in the early follicular phase of their menstrual cycle during study participation. Smokers were randomly assigned to either 200 or 400mg/day of progesterone or placebo, given in two separate doses, during clinic visit. The first 3 days of the treatment period, smokers abstained from smoking, which was verified with breath CO levels. Smokers attended an experimental session on day 4 where the number of cigarettes smoked were recorded starting 2h after the medication treatment. RESULTS:Progesterone treatment, 200mg/day, significantly improved cognitive performance in the Stroop and the Digit Symbol Substitution Test. Progesterone at 400mg/day was associated with reduced urges for smoking but did not change ad lib smoking behavior. CONCLUSIONS: These findings suggest a potential therapeutic value of progesterone for smoking cessation.
Authors: Susan L Kenford; Stevens S Smith; David W Wetter; Douglas E Jorenby; Michael C Fiore; Timothy B Baker Journal: J Consult Clin Psychol Date: 2002-02
Authors: Stephen R Rapp; Mark A Espeland; Sally A Shumaker; Victor W Henderson; Robert L Brunner; JoAnn E Manson; Margery L S Gass; Marcia L Stefanick; Dorothy S Lane; Jennifer Hays; Karen C Johnson; Laura H Coker; Maggie Dailey; Deborah Bowen Journal: JAMA Date: 2003-05-28 Impact factor: 56.272
Authors: Verica Milivojevic; Rajita Sinha; Peter T Morgan; Mehmet Sofuoglu; Helen C Fox Journal: Hum Psychopharmacol Date: 2014-11-03 Impact factor: 1.672
Authors: Kelly P Cosgrove; Irina Esterlis; Sherry A McKee; Frederic Bois; John P Seibyl; Carolyn M Mazure; Suchitra Krishnan-Sarin; Julie K Staley; Marina R Picciotto; Stephanie S O'Malley Journal: Arch Gen Psychiatry Date: 2012-04
Authors: Nicole L Tosun; Ann M Fieberg; Lynn E Eberly; Katherine A Harrison; Angela R Tipp; Alicia M Allen; Sharon S Allen Journal: Addiction Date: 2019-06-17 Impact factor: 6.526
Authors: Michael E Saladin; Erin A McClure; Nathaniel L Baker; Matthew J Carpenter; Viswanathan Ramakrishnan; Karen J Hartwell; Kevin M Gray Journal: Nicotine Tob Res Date: 2015-04 Impact factor: 4.244
Authors: Andrea H Weinberger; Philip H Smith; Sharon S Allen; Kelly P Cosgrove; Michael E Saladin; Kevin M Gray; Carolyn M Mazure; Cora Lee Wetherington; Sherry A McKee Journal: Nicotine Tob Res Date: 2015-04 Impact factor: 4.244
Authors: Raina D Pang; Madalyn M Liautaud; Matthew G Kirkpatrick; Jimi Huh; John Monterosso; Adam M Leventhal Journal: Neuropsychopharmacology Date: 2017-09-14 Impact factor: 7.853